Amid a boom in life science venture funding, ARCH Venture Partners has closed its eighth fund with more than $400 million in commitments, the firm announced Wednesday, and at least half of it is earmarked for one of the trickiest areas of innovation: emerging biomedical technology and therapeutics.
The fund matches ARCH’s previous vehicle of $400 million and could end up at $425 million, well beyond the firm’s earlier goal. It filed regulatory paperwork in April that indicated a goal of $250 million.
Image: http://www.xconomy.com
